Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
0.3400
-0.0090 (-2.58%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Polyrizon Employees
As of December 31, 2024, Polyrizon had 6 total employees, including 2 full-time and 4 part-time employees.
Employees
6
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$267,500
Market Cap
1.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PLRZ News
- 1 day ago - Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model - GlobeNewsWire
- 14 days ago - Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements - GlobeNewsWire
- 23 days ago - Polyrizon Engages Leading Branding Firm for Strategic Brand Development - GlobeNewsWire
- 24 days ago - Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement - GlobeNewsWire
- 25 days ago - Polyrizon Ltd. Announces $17.0 Million Private Placement - GlobeNewsWire
- 4 weeks ago - Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting - GlobeNewsWire
- 4 weeks ago - Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment - GlobeNewsWire
- 6 weeks ago - Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments - GlobeNewsWire